Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Trading Up 0.6%

NASDAQ COLL opened at $36.20 on Monday. The company has a fifty day simple moving average of $34.17 and a two-hundred day simple moving average of $39.45. The stock has a market cap of $1.17 billion, a P/E ratio of 17.75 and a beta of 0.74. Collegium Pharmaceutical has a 12-month low of $29.19 and a 12-month high of $50.79. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.49 earnings per share. On average, analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in COLL. Rubric Capital Management LP raised its stake in shares of Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after buying an additional 157,743 shares during the last quarter. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the period. Janus Henderson Group PLC raised its position in Collegium Pharmaceutical by 26.0% during the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares in the last quarter. Renaissance Technologies LLC raised its position in Collegium Pharmaceutical by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after acquiring an additional 18,160 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in Collegium Pharmaceutical by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after acquiring an additional 3,891 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.